Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension - Full Text View

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

This study has been completed.

Sponsored by:	Innovative Medical
Information provided by:	Innovative Medical
ClinicalTrials.gov Identifier:	NCT00348023

Purpose

Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.

Condition	Intervention	Phase
Glaucoma	Drug: Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%	Phase IV

Genetics Home Reference related topics:

early-onset glaucoma

MedlinePlus related topics:

Glaucoma High Blood Pressure

ChemIDplus related topics:

Travoprost Bimatoprost Timolol Timolol maleate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Randomized, Single Blind, Active Control, Parallel Assignment

Official Title:	Comparison of Bimatoprost 0.03% Monotherapy vs. Dual Therapy With Travoprost 0.004% and Timolol 0.5% in Patients With Glaucoma and Ocular Hypertension

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

· Male or female > 18 years of age
- Diagnosis of primary open-angle glaucoma or ocular hypertension
- Untreated IOP > 18 mm Hg in each eye at the baseline evaluation
- Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria:

· Known contraindication to bimatoprost, travoprost, timolol, or any component of any study medication
- Uncontrolled systemic disease
- Active ocular disease other than POAG or ocular hypertension
- Required use of ocular medications other than the study medications during the study (intermittent use of OTC artificial tear products will be permitted)
- History of intraocular surgery within the last 3 months
- Patient must not have discontinued use of any medication included in this study in the past for reasons of efficacy or intolerance

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00348023

Locations


United States, Pennsylvania
	Dr. Noecker
	Pittsburgh, Pennsylvania, United States, 15213

Sponsors and Collaborators

Innovative Medical

Investigators


Principal Investigator:	Robert Noecker, MD	UPMC Eye Center

More Information

Study ID Numbers:	5179
First Received:	June 30, 2006
Last Updated:	February 7, 2007
ClinicalTrials.gov Identifier:	NCT00348023
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Bimatoprost

Glaucoma

Eye Diseases

Vascular Diseases

Timolol

Travoprost

Hypertension

Ocular Hypertension

Additional relevant MeSH terms:

Neurotransmitter Agents

Molecular Mechanisms of Pharmacological Action

Adrenergic Agents

Therapeutic Uses

Physiological Effects of Drugs

Adrenergic beta-Antagonists

Adrenergic Antagonists

Cardiovascular Diseases

Cardiovascular Agents

Anti-Arrhythmia Agents

Antihypertensive Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 10, 2008